Latest news with #Watchman
Pink Villa
5 days ago
- Entertainment
- Pink Villa
Gachiakuta Chapter 140: Rudo Fights Off Mymo's Army—Recap, Release Date, Where To Read And More
The last Gachiakuta chapter, titled 'Mymo the Ruler,' saw the Choker Maker reveal how chokers are crafted. It is revealed that they are made by infusing cords with his blood and power, and that he can create them in large quantities due to possession of a Watchman series fragment. Mymo exploited the combination of this with the Chokers' registration process to take control of both the Choker Maker and the crowd. Unlike the others, Rudo's choker links directly to the maker. Mymo calls Felix and Gil to support him, boasting of achieving his ambitions. Activating his microphone, Elenhos, Mymo commands the audience to kill Rudo and his allies. Expected plot in Gachiakuta Chapter 140 Gachiakuta Chapter 140 will likely depict Rudo, Enjin, Zanka, and Riyo resisting the controlled crowd. Rudo, whose choker operates differently, may use its connection to the Choker Maker to counter Mymo's influence. The group must avoid harming innocent civilians while trying to reach Mymo. Possible strategies to sever Mymo's control or destroy the chokers may be introduced. The chapter should also reveal more about Elenhos and Mymo's techniques, and the Choker Maker might intervene to aid Rudo in neutralizing the threat to the Ground. Gachiakuta Chapter 140: Release date and where to read Gachiakuta Chapter 140 is scheduled for release on Wednesday, June 11, 2025, at 12 am JST. International readers will have early access on Tuesday, June 10, with release times adjusted to local time zones. Gachiakuta Chapter 130 can be read through Kodansha's K Manga service, available in select countries such as the US, Australia, Singapore, Thailand, Hong Kong, India, and Brazil. To read the latest chapters, users will need to purchase points, which can be done via the official website or the K Manga app. For more updates from the Gachiakuta manga, stay tuned to Pinkvilla.
Yahoo
25-05-2025
- Health
- Yahoo
Mon Medical Center achieves state first in new AFib procedure
May 25—dbeard @ Vandalia Health Mon Medical Center recently achieved another first-in-state in heart care by combining two technologies to treat atrial fibrillation — AFib. Mon Health Heart & Vascular Center electrophysiologist Dr. Salam Sbaity and his team combined the application of the Watchman and the Farapulse Pulsed Field Ablation system — both from Boston Scientific — in a single procedure. AFIb is when the top two chambers of the heart — the atria — beat too fast and with an irregular rhythm (fibrillation), Boston Scientific said. Sbaity explained why combining the two technologies is significant. AFib is the most common abnormal heart rhythm and West Virginia is among the top three states for prevalence. AFib symptoms include palpitations, dizziness and shortness of breath, he said, and can lead to heart failure, blood clots and stroke. There are two main advanced treatments. One is to treat the source of clots and stroke by closing the left atrial appendage, which extends off of the left atrium. The Watchman device is used to close it off. The other is to treat the rhythm itself, he said. Muscle sleeves lead from the atrium into four pulmonary veins and are the source of electrical instability that can start the abnormal rhythm. The abnormal rhythm is treated via cauterization, also known as ablation. The two forms of ablation used are extreme heat — radio frequency ablation — and extreme cold, cryoablation. Boston Scientific announced in January 2024 that the FDA approved a new form, pulsed field ablation, with the Farapulse. The Farapulse catheter is tipped with five circular splines that can change shapes — including a flower — to fit into the entry of veins, circle and isolate them. The Farapulse uses electrical pulses to create pores in the cell membranes and the cells die without heat or freezing, Sbaity said. It's safe for the structure of the veins and structures around them. Boston Scientific reported that 12-month data from a pivotal clinical trial to directly compare the efficacy and safety of the Farapulse system against standard-of-care ablation found that Farapulse therapy was as safe and effective as conventional thermal ablation, with statistically shorter ablation times and a quicker learning curve for physicians. "That made the procedure itself more effective and more safe, " he said. Sbaity and his partner, Dr. Matt Gaskill, performed the first Farapulse procedure in the state. "In reviewing the literature for a while, we were seeing that this is the future of ablation." It's faster, more effective and safer, he said. Both are done via a catheter through the groin and into the same chamber of the heart. So it allows the flexibility to add another procedure without increasing time and risks. The dual procedure has to be guided by internal imaging, and Sbaity took a further advanced step by employing intracardiac ultrasound — also called intracardiac echocardiography, ICE — instead of the usual transesophageal echocardiography, TEE. TEE requires a second physician sending a scope down the throat, posing the risk of esophageal damage, the American Heart Association says. ICE can be performed by the primary physician doing the catheter procedure, avoiding the additional intubation and damage risks. Only 8 % of cases of appendage closure in country are done with ICE, Sbaity said. Combining the two procedures, Sbaity said, allows him to offer the patient advanced treatment of both problems, with the risks associated with separate procedures pared down to one, and with reduced recovery time. I think this is the wave of the future, combining the two procedures together whenever both are necessary, " he said. The Mon team is participating in clinical trials comparing appendage closure against blood thinners for people who are not having problems with blood thinners, he said. One study showed closure is better statistically and better in terms of risks. "I think the other two studies will probably prove the same." What that means, he said, "if it goes that way, then anyone on blood thinner who goes for an ablation would as well want to close the appendage." This would increase the number of patients who benefit from the combined procedure. He expects most patients will want it. Sbaity said he has done just the one combined procedure so far, but five more are scheduled. "We're proud here at Mon to offer the most advanced technologies for our patients in West Virginia, " he said, "and we always want to be and have been at the forefront of innovation. That allows the population of West Virginia to have access to the most excellent, best care in the country."
Dominion Post
25-05-2025
- Health
- Dominion Post
Mon Medical Center achieves state first in new AFib procedure
dbeard@ Vandalia Health Mon Medical Center recently achieved another first-in-state in heart care by combining two technologies to treat atrial fibrillation – AFib. Farapulse images courtesy Boston Scientific Mon Health Heart & Vascular Center electrophysiologist Dr. Salam Sbaity and his team combined the application of the Watchman and the Farapulse Pulsed Field Ablation system – both from Boston Scientific – in a single procedure. AFIb is when the top two chambers of the heart – the atria – beat too fast and with an irregular rhythm (fibrillation), Boston Scientific said. Sbaity explained why combining the two technologies is significant. AFib is the most common abnormal heart rhythm and West Virginia is among the top three states for prevalence. AFib symptoms include palpitations, dizziness and shortness of breath, he said, and can lead to heart failure, blood clots and stroke. There are two main advanced treatments. One is to treat the source of clots and stroke by closing the left atrial appendage, which extends off of the left atrium. The Watchman device is used to close it off. The other is to treat the rhythm itself, he said. Muscle sleeves lead from the atrium into four pulmonary veins and are the source of electrical instability that can start the abnormal rhythm. The abnormal rhythm is treated via cauterization, also known as ablation. The two forms of ablation used are extreme heat – radio frequency ablation – and extreme cold, cryoablation. Boston Scientific announced in January 2024 that the FDA approved a new form, pulsed field ablation, with the Farapulse. The Farapulse catheter is tipped with five circular splines that can change shapes – including a flower – to fit into the entry of veins, circle and isolate them. The Farapulse uses electrical pulses to create pores in the cell membranes and the cells die without heat or freezing, Sbaity said. It's safe for the structure of the veins and structures around them. Boston Scientific reported that 12-month data from a pivotal clinical trial to directly compare the efficacy and safety of the Farapulse system against standard-of-care ablation found that Farapulse therapy was as safe and effective as conventional thermal ablation, with statistically shorter ablation times and a quicker learning curve for physicians. 'That made the procedure itself more effective and more safe,' he said. Sbaity and his partner, Dr. Matt Gaskill, performed the first Farapulse procedure in the state. 'In reviewing the literature for a while, we were seeing that this is the future of ablation.' It's faster, more effective and safer, he said. Both are done via a catheter through the groin and into the same chamber of the heart. So it allows the flexibility to add another procedure without increasing time and risks. The dual procedure has to be guided by internal imaging, and Sbaity took a further advanced step by employing intracardiac ultrasound – also called intracardiac echocardiography, ICE – instead of the usual transesophageal echocardiography, TEE. TEE requires a second physician sending a scope down the throat, posing the risk of esophageal damage, the American Heart Association says. ICE can be performed by the primary physician doing the catheter procedure, avoiding the additional intubation and damage risks. Only 8% of cases of appendage closure in country are done with ICE, Sbaity said. Combining the two procedures, Sbaity said, allows him to offer the patient advanced treatment of both problems, with the risks associated with separate procedures pared down to one, and with reduced recovery time. I think this is the wave of the future, combining the two procedures together whenever both are necessary,' he said. The Mon team is participating in clinical trials comparing appendage closure against blood thinners for people who are not having problems with blood thinners, he said. One study showed closure is better statistically and better in terms of risks. 'I think the other two studies will probably prove the same.' What that means, he said, 'if it goes that way, then anyone on blood thinner who goes for an ablation would as well want to close the appendage.' This would increase the number of patients who benefit from the combined procedure. He expects most patients will want it. Sbaity said he has done just the one combined procedure so far, but five more are scheduled. 'We're proud here at Mon to offer the most advanced technologies for our patients in West Virginia,' he said, 'and we always want to be and have been at the forefront of innovation. That allows the population of West Virginia to have access to the most excellent, best care in the country.'
Associated Press
19-05-2025
- Business
- Associated Press
CellGate Launches CellGate Academy--An Online Learning Platform for Security Access Professionals
The New Training Resource Empowers Installers, Dealers, and Property Managers to Master CellGate Solutions. CARROLLTON, Texas, May 19, 2025 /PRNewswire/ -- CellGate, a leader in wireless access control, announces the launch of CellGate Academy, a new online learning platform designed to educate and train security access professionals across the security and access control industry. This interactive training resource provides free, on-demand access to a wide range of courses tailored to CellGate's product ecosystem, enabling professionals to grow their expertise while earning valuable continuing education credits. CellGate Academy Includes: 'Training has always been a cornerstone of successful product deployment,' said Christian Morrow, Director of Marketing. 'With CellGate Academy, we're giving our partners a new, powerful way to elevate their teams, stay current with our latest innovations, and ultimately deliver more value to their customers.' CellGate Academy's courses will cover the full range of CellGate solutions, including the Company's existing Watchman® and OmniPoint® product lines, and highly anticipated new CellGate products – like Entría™ and CG Readers & Credentials. The latter two product lines are expected to launch later this summer; thus CellGate Academy's courses ensure learners are prepared to work with any solution in the CellGate ecosystem. The courses are designed for both first-time installers and seasoned integrators, and are appealing to both groups because courses can be taken at any time, whenever personal schedules permit. Key Benefits of CellGate Academy Include: CellGate Academy courses are available now at and can also be accessed via the CellGate website's Dealer Resources section. To learn more, an intro video is available on the Academy's landing page; questions may be directed to [email protected]. CellGate has been providing access control and security monitoring products utilizing cellular and internet network technology since 2006. They are the only technology company with a complete suite of cellular-based security products—encompassing integrated streaming video, access control, and camera solutions. With their Watchman, OmniPoint, Entria, and CG Readers product lines, CellGate provides a Total Property Security Access solution for virtually any property. All CellGate products are administered via TrueCloud Connect™ on Microsoft Azure's cloud service, with end user functionality accessible through the intuitive CellGate app. View original content to download multimedia: SOURCE CellGate
Time of India
24-04-2025
- Business
- Time of India
Boston Scientific raises 2025 profit forecast on strong heart device sales
Bengaluru: Boston Scientific raised its annual profit forecast after strong sales of its heart devices helped beat Wall Street expectations for first-quarter profit . Shares of the medical device maker soared nearly 10 per cent in premarket trading, as the raised forecast alleviated investor concerns about the impact of U.S. President Donald Trump's sweeping tariffs, particularly on China. The revised forecast came in "much better than expected even after reflecting tariffs", analyst Robbie Marcus wrote in a client note. Boston Scientific raised its forecast for 2025 adjusted earnings per share to a range of $2.87 to $2.94 from between $2.80 and $2.87 per share earlier. Medical devices manufacturers have benefited from elevated demand for non-urgent surgical procedures in the U.S., especially among older adults, since the second half of 2023. The trend is expected to continue this year, after health insurance giant UnitedHealth Group lowered its annual outlook last week, citing sustained high demand for medical care. On Wednesday, Boston Scientific projected an annual revenue growth of 15% to 17% from last year. The company's first-quarter revenue rose 20.9% to $4.66 billion, above estimates of $4.57 billion, according to data compiled by LSEG. Sales at its cardiovascular unit , which sells Watchman devices for stroke prevention, rose 26.2% to $3.08 billion, beating analysts' estimates of $2.97 billion. The Massachusetts-based company's key growth drivers are heart devices, including Watchman, and Farapulse, which uses short high-voltage pulses to treat certain abnormal heart rhythm conditions. In the first quarter, it earned 75 cents on an adjusted basis, topping estimates of 67 cents. Separately, the medical device maker said its finance chief Dan Brennan would retire by June-end after 30 years with the company. Jon Monson, who is currently senior vice president of investor relations, will succeed Brennan, the company said.
